Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis

Kidney International

Volumn 75, Issue 1, 2009, Pages 52-59

  Roelofs, Joris J T H ^a,b   Teske, Gwendoline J D ^a   Bonta, Peter I ^a   De Vries, Carlie J M ^a   Meijers, Joost C M ^a   Weening, Jan J ^a   Van Der Poll, Tom ^a   Florquin, Sandrine ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Fibrinolytic system; Immunology and pathology; Plasminogen activator inhibitor type 1; Pyelonephritis

Indexed keywords

AGAR; CHEMOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BLADDER; BLOOD LEVEL; CELL MIGRATION; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENE EXPRESSION; HISTOPATHOLOGY; HOST RESISTANCE; INOCULATION; KIDNEY; KIDNEY HOMOGENATE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYELONEPHRITIS; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

ACUTE DISEASE; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; IMMUNITY; KIDNEY; MICE; MICE, KNOCKOUT; NEUTROPHIL INFILTRATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYELONEPHRITIS;

EID: 58049221169     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.454     Document Type: Article

References (66)

1. Barnett BJ, Stephens DS. Urinary tract infection: an overview. Am J Med Sci 1997; 314: 245-249.
2. Mulvey MA, Schilling JD, Martinez JJ et al. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci USA 2000; 97: 8829-8835.
3. Cotton SA, Gbadegesin RA, Williams S et al. Role of TGF-beta1 in renal parenchymal scarring following childhood urinary tract infection. Kidney Int 2002; 61: 61-67.
4. Hedges S, Agace W, Svensson M et al. Uroepithelial cells are part of a mucosal cytokine network. Infect Immun 1994; 62: 2315-2321.
5. Hedges S, Svensson M, Svanborg C. Interleukin-6 response of epithelial cell lines to bacterial stimulation in vitro. Infect Immun 1992; 60: 1295-1301.
6. Khalil A, Brauner A, Bakhiet M et al. Cytokine gene expression during experimental Escherichia coli pyelonephritis in mice. J Urol 1997; 158: 1576-1580.
7. Roelofs JJ, Rouschop KM, Teske GJ et al. The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int 2006; 70: 1942-1947.
8. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82: 259-270.
9. Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928.
10. Carmeliet P, Moons L, Lijnen R et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180-3191.
11. Eitzman DT, McCoy RD, Zheng X et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237.
12. Luttun A, Lupu F, Storkebaum E et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22: 499-505.
13. Van Ness K, Chobaz-Peclat V, Castellucci M et al. Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis. Rheumatology (Oxford) 2002; 41: 136-141.
14. Kluft C, Verheijen JH, Jie AF et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610.
15. Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16: 43-47.
16. Kjoller L, Kanse SM, Kirkegaard T et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-429.
17. Czekay RP, Aertgeerts K, Curriden SA et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781-791.
18. Cao C, Lawrence DA, Li Y et al. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006; 25: 1860-1870.
19. Rijneveld AW, Florquin S, Bresser P et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102: 934-939.
20. Renckens R, Roelofs JJ, Bonta PI et al. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 2007; 109: 1593-1601.
21. de Boer JP, Creasy AA, Chang A et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 1993; 39: 59-67.
22. Paramo JA, Perez JL, Serrano M et al. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost 1990; 64: 3-6.
23. Zeerleder S, Schroeder V, Hack CE et al. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-212.
24. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 1346-1353.
25. Zhang RL, Zhang ZG, Chopp M et al. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999; 30: 624-629.
26. Webb NJ, Brenchley PE. Cytokines and cell adhesion molecules in the inflammatory response during acute pyelonephritis. Nephron Exp Nephrol 2004; 96: e1-e6.
27. Juhan-Vague I, Moerman B, De Cock F et al. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530.
28. Harbeck N, Kates RE, Gauger K et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004; 91: 450-456.
29. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
30. Paueksakon P, Revelo MP, Ma LJ et al. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 2002; 61: 2142-2148.
31. Nicholas SB, Aguiniga E, Ren Y et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005; 67: 1297-1307.
32. Hamano K, Iwano M, Akai Y et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 2002; 39: 695-705.
33. Xu Y, Hagege J, Mougenot B et al. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 1996; 50: 2011-2019.
34. Rondeau E, Mougenot B, Lacave R et al. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin Nephrol 1990; 33: 55-60.
35. Shihab FS, Yamamoto T, Nast CC et al. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol 1995; 6: 286-294.
36. Wang Y, Pratt JR, Hartley B et al. Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. Kidney Int 1997; 52: 371-377.
37. Collins SJ, Alexander SL, Lopez-Guisa JM et al. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 2006; 104: e23-e34.
38. Oda T, Jung YO, Kim HS et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 60: 587-596.
39. Carmeliet P, Stassen JM, Schoonjans L et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
40. Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J Am Soc Nephrol 2004; 15: 844-853.
41. Kitching AR, Holdsworth SR, Ploplis VA et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997; 185: 963-968.
42. Kitching AR, Kong YZ, Huang XR et al. Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14: 1487-1495.
43. Ivanyi B, Thoenes W. Microvascular injury and repair in acute human bacterial pyelonephritis. Virchows Arch A Pathol Anat Histopathol 1987; 411: 257-265.
44. Haraoka M, Hang L, Frendeus B et al. Neutrophil recruitment and resistance to urinary tract infection. J Infect Dis 1999; 180: 1220-1229.
45. Patole PS, Schubert S, Hildinger K et al. Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis. Kidney Int 2005; 68: 2582-2587.
46. Chassin C, Goujon JM, Darche S et al. Renal collecting duct epithelial cells react to pyelonephritis-associated Escherichia coli by activating distinct TLR4-dependent and -independent inflammatory pathways. J Immunol 2006; 177: 4773-4784.
47. Ward JR, Dower SK, Whyte MK et al. Potentiation of TLR4 signalling by plasmin activity. Biochem Biophys Res Commun 2006; 341: 299-303.
48. Kwak SH, Wang XQ, He Q et al. Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway. Thromb Haemost 2006; 95: 829-835.
49. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-442.
50. Chavakis T, Kanse SM, Yutzy B et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91: 2305-2312.
51. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
52. Marshall LJ, Ramdin LS, Brooks T et al. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003; 171: 2057-2065.
53. Samanta AK, Oppenheim JJ, Matsushima K. Interleukin 8 (monocyte-derived neutrophil chemotactic factor) dynamically regulates its own receptor expression on human neutrophils. J Biol Chem 1990; 265: 183-189.
54. Hechtman DH, Cybulsky MI, Fuchs HJ et al. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991; 147: 883-892.
55. Simonet WS, Hughes TM, Nguyen HQ et al. Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. J Clin Invest 1994; 94: 1310-1319.
56. Olszyna DP, Opal SM, Prins JM et al. Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-alpha, and epithelial cell-derived neutrophil-activating protein-78 in urine of patients with urosepsis. J Infect Dis 2000; 182: 1731-1737.
57. Frendeus B, Godaly G, Hang L et al. Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart. J Exp Med 2000; 192: 881-890.
58. Hang L, Frendeus B, Godaly G et al. Interleukin-8 receptor knockout mice have subepithelial neutrophil entrapment and renal scarring following acute pyelonephritis. J Infect Dis 2000; 182: 1738-1748.
59. Artifoni L, Negrisolo S, Montini G et al. Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J Urol 2007; 177: 1102-1106.
60. Carmeliet P, Kieckens L, Schoonjans L et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-2755.
61. Olszyna DP, Florquin S, Sewnath M et al. CXC chemokine receptor 2 contributes to host defense in murine urinary tract infection. J Infect Dis 2001; 184: 301-307.
62. Hopkins WJ, Gendron-Fitzpatrick A, Balish E et al. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect Immun 1998; 66: 2798-2802.
63. Rouschop KM, Sylva M, Teske GJD et al. Urothelial CD44 facilitates Escherichia coli infection of the murine urinary tract. J Immunol 2006; 177: 7225-7232.
64. Roelofs JJ, Rouschop KM, Leemans JC et al. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol 2006; 17: 131-140.
65. Boot RG, van Achterberg TA, van Aken BE et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 687-694.
66. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.